A limited structural modification results in a significantly more efficacious diazachrysene-based filovirus inhibitor

Viruses

Volumn 4, Issue 8, 2012, Pages 1279-1288

  Selaković, Života ^a   Opsenica, Dejan ^b   Eaton, Brett ^c   Retterer, Cary ^c   Bavari, Sina ^c   Burnett, James C ^d   Šolaja, Bogdan A ^a   Panchal, Rekha G ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

Antiviral; Diazachrysene; Ebola virus; Filovirus; Inhibitory efficacy; Marburg virus; Small molecule; Toxicity

Indexed keywords

ANTIVIRUS AGENT; DIAZACHRYSENE BASED FILOVIRUS INHIBITOR DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HUMAN; HUMAN CELL; IC 50; VIRUS REPLICATION;

ANTIVIRAL; DIAZACHRYSENE; EBOLA VIRUS; FILOVIRUS; INHIBITORY EFFICACY; MARBURG VIRUS; SMALL MOLECULE; TOXICITY;

ANTIVIRAL AGENTS; EBOLAVIRUS; FILOVIRIDAE INFECTIONS; HUMANS; MARBURGVIRUS; MOLECULAR STRUCTURE; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EBOLA VIRUS; LAKE VICTORIA MARBURGVIRUS; MARBURGVIRUS; PRIMATES;

EID: 84868605426     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v4081279     Document Type: Article

References (15)

1. Bausch, D.G.; Towner, J.S.; Dowell, S.F.; Kaducu, F.; Lukwiya, M.; Sanchez, A.; Nichol, S.T.; Ksiazek, T.G.; Rollin, P.E. Assessment of the risk of ebola virus transmission from bodily fluids and fomites. J. Infect. Dis. 2007, 196, S142-S147.
2. Available online: http://www.Bt.Cdc.Gov/agent/agentlist-category.Asp (accessed on 24 June 2012).
3. Kuhn, J.H. Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Arch. Virol. Suppl. 2008, 20, 13-360.
4. Bradfute, S.B.; Dye, J.M., Jr.; Bavari, S. Filovirus vaccines. Hum. Vaccin 2011, 7, 701-711.
5. Sullivan, N.J.; Geisbert, T.W.; Geisbert, J.B.; Shedlock, D.J.; Xu, L.; Lamoreaux, L.; Custers, J.H.; Popernack, P.M.; Yang, Z.Y.; Pau, M.G. et al. Immune protection of nonhuman primates against ebola virus with single low-dose adenovirus vectors encoding modified gps. PLoS Med. 2006, 3, e177.
6. Sullivan, N.J.; Sanchez, A.; Rollin, P.E.; Yang, Z.Y.; Nabel, G.J. Development of a preventive vaccine for ebola virus infection in primates. Nature 2000, 408, 605-609.
7. Warren, T.K.; Warfield, K.L.; Wells, J.; Swenson, D.L.; Donner, K.S.; van Tongeren, S.A.; Garza, N.L.; Dong, L.; Mourich, D.V.; Crumley, S. et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 2010, 16, 991-994.
8. Warfield, K.L.; Panchal, R.G.; Aman, M.J.; Bavari, S. Antisense treatments for biothreat agents. Curr. Opin. Mol. Ther. 2006, 8, 93-103.
9. Warren, T.K.; Shurtleff, A.C.; Bavari, S. Advanced morpholino oligomers: A novel approach to antiviral therapy. Antivir. Res. 2012, 94, 80-88.
10. Swenson, D.L.; Warfield, K.L.; Warren, T.K.; Lovejoy, C.; Hassinger, J.N.; Ruthel, G.; Blouch, R.E.; Moulton, H.M.; Weller, D.D.; Iversen, P.L. et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against ebola virus infection. Antimicrob. Agents Chemother. 2009, 53, 2089-2099.
11. Panchal, R.G.; Reid, S.P.; Tran, J.P.; Bergeron, A.A.; Wells, J.; Kota, K.P.; Aman, J.; Bavari, S. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity. Antivir. Res. 2012, 93, 23-29.
12. Reid, S.P.; Shurtleff, A.C.; Bavari, S. Emerging therapeutic options against filoviruses. Drugs Future 2012, 37, 343-352.
13. Aman, M.J.; Kinch, M.S.; Warfield, K.; Warren, T.; Yunus, A.; Enterlein, S.; Stavale, E.; Wang, P.; Chang, S.; Tang, Q. et al. Development of a broad-spectrum antiviral with activity against ebola virus. Antivir. Res. 2009, 83, 245-251.
14. Opsenica, I.; Burnett, J.C.; Gussio, R.; Opsenica, D.; Todorovic, N.; Lanteri, C.A.; Sciotti, R.J.; Gettayacamin, M.; Basilico, N.; Taramelli, D. et al. A chemotype that inhibits three unrelated pathogenic targets: The botulinum neurotoxin serotype a light chain, p. Falciparum malaria, and the ebola filovirus. J. Med. Chem. 2011, 54, 1157-1169.
15. Panchal, R.G.; Kota, K.P.; Spurgers, K.B.; Ruthel, G.; Tran, J.P.; Boltz, R.C.; Bavari, S. Development of high-content imaging assays for lethal viral pathogens. J. Biomol. Screen 2010, 15, 755-765.